HCA Healthcare (HCA) 10-Q 9 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Apr. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	HCA
Entity Registrant Name	HCA HEALTHCARE, INC.
Entity Central Index Key	860,730
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		366,904,600

Condensed Consolidated Income S

Condensed Consolidated Income Statements (Unaudited) - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Revenues before provision for doubtful accounts	$ 11,383	$ 11,050
Provision for doubtful accounts	760	790
Revenues	10,623	10,260
Salaries and benefits	4,901	4,702
Supplies	1,797	1,714
Other operating expenses	1,930	1,853
Equity in earnings of affiliates	(10)	(12)
Depreciation and amortization	521	479
Interest expense	419	416
Losses (gains) on sales of facilities	(1)	1
Legal claim costs		12
Total expenses including equity in earnings of affiliates	9,557	9,165
Income before income taxes	1,066	1,095
Provision for income taxes	289	284
Net income	777	811
Net income attributable to noncontrolling interests	118	117
Net income attributable to HCA Healthcare, Inc.	$ 659	$ 694
Per share data:
Basic earnings per share	$ 1.78	$ 1.75
Diluted earnings per share	$ 1.74	$ 1.69
Shares used in earnings per share calculations (in millions):
Basic	370,289	396,397
Diluted	379,980	410,575

Condensed Consolidated Comprehe

Condensed Consolidated Comprehensive Income Statements (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 777	$ 811
Other comprehensive income (loss) before taxes:
Foreign currency translation	10	(43)
Unrealized gains on available-for-sale securities	3	2
Defined benefit plans	0	0
Pension costs included in salaries and benefits	5	4
Total defined benefit plans	5	4
Change in fair value of derivative financial instruments	3	(38)
Interest costs included in interest expense	7	28
Total change in fair value of derivative financial instruments	10	(10)
Other comprehensive income (loss) before taxes	28	(47)
Income taxes (benefits) related to other comprehensive income items	10	(18)
Other comprehensive income (loss)	18	(29)
Comprehensive income	795	782
Comprehensive income attributable to noncontrolling interests	118	117
Comprehensive income attributable to HCA Healthcare, Inc.	$ 677	$ 665

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 753	$ 646
Accounts receivable, less allowance for doubtful accounts of $4,880 and $4,988	5,664	5,826
Inventories	1,501	1,503
Other	1,119	1,111
Total current assets	9,037	9,086
Property and equipment, at cost	37,588	37,055
Accumulated depreciation	(21,126)	(20,703)
Property and equipment, net	16,462	16,352
Investments of insurance subsidiaries	349	336
Investments in and advances to affiliates	194	206
Goodwill and other intangible assets	6,754	6,704
Other	999	1,074
Total assets	33,795	33,758
Current liabilities:
Accounts payable	2,233	2,318
Accrued salaries	1,150	1,265
Other accrued expenses	1,868	2,035
Long-term debt due within one year	212	216
Total current liabilities	5,463	5,834
Long-term debt, less net debt issuance costs of $165 and $170	31,302	31,160
Professional liability risks	1,134	1,148
Income taxes and other liabilities	1,253	1,249
Stockholders' deficit:
Common stock $0.01 par; authorized 1,800,000,000 shares; outstanding 368,694,700 shares in 2017 and 370,535,900 shares in 2016	4	4
Accumulated other comprehensive loss	(320)	(338)
Retained deficit	(6,701)	(6,968)
Stockholders' deficit attributable to HCA Healthcare, Inc.	(7,017)	(7,302)
Noncontrolling interests	1,660	1,669
Total stockholders' deficit	(5,357)	(5,633)
Total liabilities and stockholders' deficit	$ 33,795	$ 33,758

Condensed Consolidated Balance5

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for Accounts receivable	$ 4,880	$ 4,988
Debt issuance cost	$ 165	$ 170
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	1,800,000,000	1,800,000,000
Common stock, shares outstanding	368,694,700	370,535,900

Condensed Consolidated Statemen

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net income	$ 777	$ 811
Increase (decrease) in cash from operating assets and liabilities:
Accounts receivable	(592)	(789)
Provision for doubtful accounts	760	790
Accounts receivable, net	168	1
Inventories and other assets	3	14
Accounts payable and accrued expenses	(591)	(371)
Depreciation and amortization	521	479
Income taxes	292	360
Losses (gains) on sales of facilities	(1)	1
Legal claim costs		12
Amortization of debt issuance costs	8	10
Share-based compensation	73	65
Other	30	17
Net cash provided by (used in) operating activities	1,280	1,399
Cash flows from investing activities:
Purchase of property and equipment	(571)	(509)
Acquisition of hospitals and health care entities	(90)	(9)
Disposal of hospitals and health care entities	4	4
Change in investments	(19)	11
Other	7	7
Net cash used in investing activities	(669)	(496)
Cash flows from financing activities:
Issuances of long-term debt		3,000
Net change in revolving bank credit facilities	160	(930)
Repayment of long-term debt	(43)	(2,011)
Distributions to noncontrolling interests	(145)	(111)
Payment of debt issuance costs	(2)	(22)
Repurchases of common stock	(424)	(621)
Other	(50)	(97)
Net cash (used in) provided by financing activities	(504)	(792)
Change in cash and cash equivalents	107	111
Cash and cash equivalents at beginning of period	646	741
Cash and cash equivalents at end of period	753	852
Interest payments	540	490
Income tax refunds, net	$ (3)	$ (76)

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	NOTE 1 — BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Reporting Entity HCA Healthcare, Inc. (formerly known as HCA Holdings, Inc.) is a holding company whose affiliates own and operate hospitals and related health care entities. The term “affiliates” includes direct and indirect subsidiaries of HCA Healthcare, Inc. and partnerships and joint ventures in which such subsidiaries are partners. At March 31, 2017, these affiliates owned and operated 171 hospitals, 118 freestanding surgery centers and provided extensive outpatient and ancillary services. HCA Healthcare, Inc.’s facilities are located in 20 states and England. The terms “Company,” “HCA,” “we,” “our” or “us,” as used herein and unless otherwise stated or indicated by context, refer to HCA Healthcare, Inc. and its affiliates. The terms “facilities” or “hospitals” refer to entities owned and operated by affiliates of HCA and the term “employees” refers to employees of affiliates of HCA. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal and recurring nature. The majority of our expenses are “costs of revenues” items. Costs that could be classified as general and administrative would include our corporate office costs, which were $90 million and $85 million for the quarters ended March 31, 2017 and 2016, respectively. Operating results for the quarter ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. For further information, refer to the consolidated financial statements and footnotes thereto included in our annual report on Form 10-K for the year ended December 31, 2016. Revenues Revenues are recorded during the period the health care services are provided, based upon the estimated amounts due from the patients and third-party payers. Third-party payers include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans and commercial insurance companies (including plans offered through the health insurance exchanges), and employers. Estimates of contractual allowances under managed care health plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record a provision for doubtful accounts (based primarily on historical collection experience) related to uninsured accounts to record net self pay revenues at the estimated amounts we expect to collect. Our revenues from third party payers, the uninsured and other for the quarters ended March 31, 2017 and 2016 are summarized in the following table (dollars in millions): 2017 Ratio 2016 Ratio Medicare $ 2,405 22.6 % $ 2,266 22.1 % Managed Medicare 1,203 11.3 1,104 10.8 Medicaid 373 3.5 427 4.2 Managed Medicaid 641 6.0 597 5.8 Managed care and other insurers 5,926 55.8 5,702 55.6 International (managed care and other insurers) 269 2.5 317 3.1 10,817 101.7 10,413 101.6 Uninsured 225 2.1 189 1.8 Other 341 3.2 448 4.4 Revenues before provision for doubtful accounts 11,383 107.0 11,050 107.8 Provision for doubtful accounts (760 ) (7.0 ) (790 ) (7.8 ) Revenues $ 10,623 100.0 % $ 10,260 100.0 % Recent Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) and the International Accounting Standards Board issued a final, converged, principles-based standard on revenue recognition. Companies across all industries will use a five-step model to recognize revenue from customer contracts. The new standard, which replaces nearly all existing revenue recognition guidance, will require significant management judgments and change the way many companies recognize revenue in their financial statements. In July 2015, the FASB decided to defer the effective date of the new revenue standard by one year to annual and interim periods beginning after December 15, 2017 for public entities and permit entities to adopt one year earlier if they choose. The FASB decided, based on its outreach to various stakeholders and continuing amendments to the new revenue standard, that a deferral was necessary to provide adequate time to effectively implement the new standard. We are continuing to evaluate the effects the adoption of this standard will have on our financial statements and financial disclosures. We believe the most significant impact will be to the presentation of our income statement where the provision for doubtful accounts will be recorded as a direct reduction to revenues and will not be presented as a separate line item. We expect to adopt the new standard using the full retrospective application, and we do not believe the adoption will have a significant impact on our recognition of net revenues for any period. In February 2016, the FASB issued Accounting Standards Update 2016-02, Leases In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment In March 2017, the FASB issued ASU 2017-07, Compensation — Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost Reclassifications Certain prior year amounts have been reclassified to conform to the current year presentation.

Acquisitions and Dispositions

Acquisitions and Dispositions	3 Months Ended
	Mar. 31, 2017
Business Combinations [Abstract]
Acquisitions and Dispositions	NOTE 2 — ACQUISITIONS AND DISPOSITIONS During the quarters ended March 31, 2017 and 2016, we paid $90 million and $9 million, respectively, to acquire other nonhospital health care entities. During the quarter ended March 31, 2017, we received proceeds of $4 million and recognized a net pretax gain of $1 million related to sales of real estate and other investments. During the quarter ended March 31, 2016, we received proceeds of $4 million and recognized a net pretax loss of $1 million related to sales of real estate and other investments. During the April 1, 2017 through May 9, 2017 period, we entered into agreements to purchase six hospitals for an aggregate purchase price of approximately $950 million. Subject to regulatory reviews, the transactions are currently expected to close during the second and third quarters of 2017. We intend to fund the purchases through amounts available under our revolving credit facility or anticipated access to debt markets.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 3 — INCOME TAXES Our liability for unrecognized tax benefits was $405 million, including accrued interest of $42 million, as of March 31, 2017 ($418 million and $45 million, respectively, as of December 31, 2016). Unrecognized tax benefits of $134 million ($137 million as of December 31, 2016) would affect the effective rate, if recognized. Our provision for income taxes for the quarters ended March 31, 2017 and 2016 included tax benefits of $67 million and $74 million, respectively, related to the settlement of employee equity awards resulting in the recognition of excess tax benefits (when the deductible amount related to the settlement of employee equity awards for tax purposes exceeds the cumulative compensation cost recognized for financial reporting purposes). We are subject to examination by federal, state and foreign taxing authorities. Depending on the resolution of any federal, state and foreign tax disputes, the completion of examinations by federal, state or foreign taxing authorities, or the expiration of statutes of limitation for specific taxing jurisdictions, we believe it is reasonably possible that our liability for unrecognized tax benefits may significantly increase or decrease within the next 12 months. However, we are currently unable to estimate the range of any possible change.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share	NOTE 4 — EARNINGS PER SHARE We compute basic earnings per share using the weighted average number of common shares outstanding. We compute diluted earnings per share using the weighted average number of common shares outstanding, plus the dilutive effect of outstanding equity awards and potential shares, computed using the treasury stock method. The following table sets forth the computation of basic and diluted earnings per share for the quarters ended March 31, 2017 and 2016 (dollars and shares in millions, except per share amounts): 2017 2016 Net income attributable to HCA Healthcare, Inc. $ 659 $ 694 Weighted average common shares outstanding 370.289 396.397 Effect of dilutive incremental shares 9.691 14.178 Shares used for diluted earnings per share 379.980 410.575 Earnings per share: Basic earnings per share $ 1.78 $ 1.75 Diluted earnings per share $ 1.74 $ 1.69

Investments of Insurance Subsid

Investments of Insurance Subsidiaries	3 Months Ended
	Mar. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Investments of Insurance Subsidiaries	NOTE 5 — INVESTMENTS OF INSURANCE SUBSIDIARIES A summary of our insurance subsidiaries’ investments at March 31, 2017 and December 31, 2016 follows (dollars in millions): March 31, 2017 Amortized Unrealized Fair Gains Losses Debt securities: States and municipalities $ 355 $11 $— $ 366 Money market funds 29 — — 29 384 11 — 395 Equity securities 1 3 — 4 $ 385 $14 $— 399 Amounts classified as current assets (50 ) Investment carrying value $ 349 December 31, 2016 Amortized Unrealized Fair Gains Losses Debt securities: States and municipalities $ 345 $9 $(1 ) $ 353 Money market funds 28 — — 28 373 9 (1 ) 381 Equity securities 1 3 — 4 $ 374 $12 $(1 ) 385 Amounts classified as current assets (49 ) Investment carrying value $ 336 At March 31, 2017 and December 31, 2016, the investments of our insurance subsidiaries were classified as “available-for-sale.” Changes in temporary unrealized gains and losses are recorded as adjustments to other comprehensive income (loss). Scheduled maturities of investments in debt securities at March 31, 2017 were as follows (dollars in millions): Amortized Fair Due in one year or less $ 98 $ 98 Due after one year through five years 78 81 Due after five years through ten years 164 172 Due after ten years 44 44 $ 384 $ 395 The average expected maturity of the investments in debt securities at March 31, 2017 was 3.9 years, compared to the average scheduled maturity of 5.6 years. Expected and scheduled maturities may differ because the issuers of certain securities have the right to call, prepay or otherwise redeem such obligations prior to their scheduled maturity date.

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	NOTE 6 — FINANCIAL INSTRUMENTS Interest Rate Swap Agreements We have entered into interest rate swap agreements to manage our exposure to fluctuations in interest rates. These swap agreements involve the exchange of fixed and variable rate interest payments between two parties based on common notional principal amounts and maturity dates. Pay-fixed interest rate swaps effectively convert LIBOR indexed variable rate obligations to fixed interest rate obligations. The interest payments under these agreements are settled on a net basis. The net interest payments, based on the notional amounts in these agreements, generally match the timing of the related liabilities for the interest rate swap agreements which have been designated as cash flow hedges. The notional amounts of the swap agreements represent amounts used to calculate the exchange of cash flows and are not our assets or liabilities. Our credit risk related to these agreements is considered low because the swap agreements are with creditworthy financial institutions. The following table sets forth our interest rate swap agreements, which have been designated as cash flow hedges, at March 31, 2017 (dollars in millions): Notional Maturity Date Fair Pay-fixed interest rate swaps $ 1,000 December 2017 $ (8 ) Pay-fixed interest rate swaps 2,000 December 2021 37 During the next 12 months, we estimate $13 million will be reclassified from other comprehensive income (“OCI”) to interest expense. Derivatives — Results of Operations The following table presents the effect of our interest rate swaps on our results of operations for the quarter ended March 31, 2017 (dollars in millions): Derivatives in Cash Flow Hedging Relationships Amount of Gain Location of Loss Amount of Loss Interest rate swaps $ 2 Interest expense $ 7

Assets and Liabilities Measured

Assets and Liabilities Measured at Fair Value	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value	NOTE 7 — ASSETS AND LIABILITIES MEASURED AT FAIR VALUE Accounting Standards Codification 820, Fair Value Measurements and Disclosures Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input significant to the fair value measurement in its entirety. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment. Cash Traded Investments Our cash traded investments are generally classified within Level 1 or Level 2 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Certain types of cash traded instruments are classified within Level 3 of the fair value hierarchy because they trade infrequently and therefore have little or no price transparency. The valuation of these securities involves the consideration of market factors and management’s judgment. Derivative Financial Instruments We have entered into interest rate swap agreements to manage our exposure to fluctuations in interest rates. The valuation of these instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. We incorporate credit valuation adjustments to reflect both our own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements of these instruments. Although we determined the majority of the inputs used to value our derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with our derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. We assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our derivative positions, and at March 31, 2017 and December 31, 2016, we determined the credit valuation adjustments were not significant to the overall valuation of our derivatives. The following tables summarize our assets and liabilities measured at fair value on a recurring basis as of March 31, 2017 and December 31, 2016, aggregated by the level in the fair value hierarchy within which those measurements fall (dollars in millions): March 31, 2017 Fair Value Fair Value Measurements Using Quoted Prices in Significant Other Significant Assets: Investments of insurance subsidiaries: Debt securities: States and municipalities $ 366 $ — $ 360 $ 6 Money market funds 29 29 — — 395 29 360 6 Equity securities 4 4 — — Investments of insurance subsidiaries 399 33 360 6 Less amounts classified as current assets (50 ) (29 ) (21 ) — $ 349 $ 4 $ 339 $ 6 Interest rate swaps (Other) $ 37 $ — $ 37 $ — Liabilities: Interest rate swaps (Income taxes and other liabilities) $ 8 $ — $ 8 $ — December 31, 2016 Fair Value Measurements Using Fair Value Quoted Prices in Significant Other Significant Assets: Investments of insurance subsidiaries: Debt securities: States and municipalities $ 353 $ — $ 347 $ 6 Money market funds 28 28 — — 381 28 347 6 Equity securities 4 4 — — Investments of insurance subsidiaries 385 32 347 6 Less amounts classified as current assets (49 ) (28 ) (21 ) — $ 336 $ 4 $ 326 $ 6 Interest rate swaps (Other) $ 31 $ — $ 31 $ — Liabilities: Interest rate swaps (Income taxes and other liabilities) $ 12 $ — $ 12 $ — The estimated fair value of our long-term debt was $33.267 billion and $32.833 billion at March 31, 2017 and December 31, 2016, respectively, compared to carrying amounts, excluding net debt issuance costs, aggregating $31.679 billion and $31.546 billion, respectively. The estimates of fair value are generally based upon the quoted market prices or quoted market prices for similar issues of long-term debt with the same maturities.

Long-Term Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Long-Term Debt	NOTE 8 — LONG-TERM DEBT A summary of long-term debt at March 31, 2017 and December 31, 2016, including related interest rates at March 31, 2017, follows (dollars in millions): March 31, December 31, Senior secured asset-based revolving credit facility (effective interest rate of 2.4%) $ 3,080 $ 2,920 Senior secured revolving credit facility — — Senior secured term loan facilities (effective interest rate of 3.5%) 3,963 3,981 Senior secured notes (effective interest rate of 5.4%) 13,800 13,800 Other senior secured debt (effective interest rate of 5.8%) 584 593 Senior secured debt 21,427 21,294 Senior unsecured notes (effective interest rate of 6.5%) 10,252 10,252 Net debt issuance costs (165 ) (170 ) Total debt (average life of 6.1 years, rates averaging 5.2%) 31,514 31,376 Less amounts due within one year 212 216 $ 31,302 $ 31,160 2016 Activity During August 2016, we issued $1.200 billion aggregate principal amount of 4.500% senior secured notes due 2027. We used the net proceeds for general corporate purposes and to retire a portion of one of our senior secured term loans. We also entered into a joinder agreement to retire the remaining portion of this senior secured term loan using proceeds from a new $1.200 billion senior secured term loan facility maturing in February 2024. During March 2016, we issued $1.500 billion aggregate principal amount of 5.250% senior secured notes due 2026. We used the net proceeds for general corporate purposes and to retire a portion of one of our senior secured term loans. We also entered into a joinder agreement to retire the remaining portion of this senior secured term loan using proceeds from a new $1.500 billion senior secured term loan facility maturing in March 2023.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Contingencies	NOTE 9 — CONTINGENCIES We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. We are also subject to claims and suits arising in the ordinary course of business, including claims for personal injuries or wrongful restriction of, or interference with, physicians’ staff privileges. In certain of these actions the claimants may seek punitive damages against us which may not be covered by insurance. We are also subject to claims by various taxing authorities for additional taxes and related interest and penalties. The resolution of any such lawsuits, claims or legal and regulatory proceedings could have a material, adverse effect on our results of operations, financial position or liquidity. Health care companies are subject to numerous investigations by various governmental agencies. Under the federal False Claims Act (“FCA”), private parties have the right to bring qui tam

Capital Structure

Capital Structure	3 Months Ended
	Mar. 31, 2017
Text Block [Abstract]
Capital Structure	NOTE 10 — CAPITAL STRUCTURE The changes in stockholders’ deficit, including changes in stockholders’ deficit attributable to HCA Healthcare, Inc. and changes in equity attributable to noncontrolling interests, are as follows (dollars and shares in millions): Equity (Deficit) Attributable to HCA Healthcare, Inc. Equity Total Common Stock Capital in Accumulated Retained Shares Par Value Balances at December 31, 2016 370.536 $ 4 $ — $ (338 ) $ (6,968 ) $ 1,669 $ (5,633 ) Comprehensive income — — — 18 659 118 795 Repurchase of common stock (5.121 ) — (32 ) — (392 ) — (424 ) Distributions — — — — — (145 ) (145 ) Share-based benefit plans 3.280 — 35 — — — 35 Other — — (3 ) — — 18 15 Balances at March 31, 2017 368.695 $ 4 $ — $ (320 ) $ (6,701 ) $ 1,660 $ (5,357 ) During the quarter ended March 31, 2017, we repurchased 5.121 million shares of our common stock at an average price of $82.83 per share through market purchases pursuant to the $2.0 billion share repurchase program authorized during November 2016. At March 31, 2017, we had $1.429 billion of repurchase authorization available under the November 2016 authorization. The components of accumulated other comprehensive loss are as follows (dollars in millions): Unrealized Foreign Defined Change Total Balances at December 31, 2016 $ 7 $ (211 ) $ (146 ) $ 12 $ (338 ) Unrealized gains on available-for-sale securities, net of $1 of income taxes 2 — — — 2 Foreign currency translation adjustments, net of $4 of income taxes — 6 — — 6 Change in fair value of derivative instruments, net of $1 of income taxes — — — 2 2 Expense reclassified into operations from other comprehensive income, net of $2 and $2, respectively, income tax benefits — — 3 5 8 Balances at March 31, 2017 $ 9 $ (205 ) $ (143 ) $ 19 $ (320 )

Segment and Geographic Informat

Segment and Geographic Information	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Segment and Geographic Information	NOTE 11 — SEGMENT AND GEOGRAPHIC INFORMATION We operate in one line of business, which is operating hospitals and related health care entities. We operate in two geographically organized groups: the National and American Groups. The National Group includes 85 hospitals located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia, and the American Group includes 80 hospitals located in Colorado, northern Georgia, Kansas, southern Kentucky, Louisiana, Mississippi, Missouri, Oklahoma, Tennessee and Texas. We also operate six hospitals in England, and these facilities are included in the Corporate and other group. Adjusted segment EBITDA is defined as income before depreciation and amortization, interest expense, losses (gains) on sales of facilities, legal claim costs, income taxes and net income attributable to noncontrolling interests. We use adjusted segment EBITDA as an analytical indicator for purposes of allocating resources to geographic areas and assessing their performance. Adjusted segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Adjusted segment EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and the items excluded from adjusted segment EBITDA are significant components in understanding and assessing financial performance. Because adjusted segment EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, adjusted segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. The geographic distributions of our revenues, equity in earnings of affiliates, adjusted segment EBITDA and depreciation and amortization for the quarters ended March 31, 2017 and 2016 are summarized in the following table (dollars in millions): 2017 2016 Revenues: National Group $ 5,148 $ 4,967 American Group 4,995 4,786 Corporate and other 480 507 $ 10,623 $ 10,260 Equity in earnings of affiliates: National Group $ (5 ) $ (2 ) American Group (8 ) (9 ) Corporate and other 3 (1 ) $ (10 ) $ (12 ) Adjusted segment EBITDA: National Group $ 1,131 $ 1,138 American Group 1,007 982 Corporate and other (133 ) (117 ) $ 2,005 $ 2,003 Depreciation and amortization: National Group $ 214 $ 197 American Group 238 219 Corporate and other 69 63 $ 521 $ 479 Adjusted segment EBITDA $ 2,005 $ 2,003 Depreciation and amortization 521 479 Interest expense 419 416 Losses (gains) on sales of facilities (1 ) 1 Legal claim costs — 12 Income before income taxes $ 1,066 $ 1,095

Supplemental Condensed Consolid

Supplemental Condensed Consolidating Financial Information	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Condensed Consolidating Financial Information	NOTE 12 — SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION During December 2012, HCA Healthcare, Inc. issued $1.000 billion aggregate principal amount of 6.250% senior unsecured notes due 2021. These notes are senior unsecured obligations and are not guaranteed by any of our subsidiaries. HCA Inc., a direct wholly-owned subsidiary of HCA Healthcare, Inc., is the obligor under a significant portion of our other indebtedness, including our senior secured credit facilities, senior secured notes and senior unsecured notes (other than the senior unsecured notes issued by HCA Healthcare, Inc.). The senior secured notes and senior unsecured notes issued by HCA Inc. are fully and unconditionally guaranteed by HCA Healthcare, Inc. The senior secured credit facilities and senior secured notes are fully and unconditionally guaranteed by substantially all existing and future, direct and indirect, 100% owned material domestic subsidiaries that are “Unrestricted Subsidiaries” under our Indenture dated December 16, 1993 (except for certain special purpose subsidiaries that only guarantee and pledge their assets under our senior secured asset-based revolving credit facility). Our summarized condensed consolidating comprehensive income statements for the quarters ended March 31, 2017 and 2016, condensed consolidating balance sheets at March 31, 2017 and December 31, 2016 and condensed consolidating statements of cash flows for the quarters ended March 31, 2017 and 2016, segregating HCA Healthcare, Inc. issuer, HCA Inc. issuer, the subsidiary guarantors, the subsidiary non-guarantors and eliminations, follow: HCA HEALTHCARE, INC. CONDENSED CONSOLIDATING COMPREHENSIVE INCOME STATEMENT FOR THE QUARTER ENDED MARCH 31, 2017 (Dollars in millions) HCA HCA Inc. Subsidiary Subsidiary Eliminations Condensed Revenues before provision for doubtful accounts $ — $ — $ 5,853 $ 5,530 $ — $ 11,383 Provision for doubtful accounts — — 419 341 — 760 Revenues — — 5,434 5,189 — 10,623 Salaries and benefits — — 2,466 2,435 — 4,901 Supplies — — 951 846 — 1,797 Other operating expenses 1 — 927 1,002 — 1,930 Equity in earnings of affiliates (608 ) — (1 ) (9 ) 608 (10 ) Depreciation and amortization — — 251 270 — 521 Interest expense 16 733 (269 ) (61 ) — 419 Gains on sales of facilities — — — (1 ) — (1 ) Management fees — — (210 ) 210 — — (591 ) 733 4,115 4,692 608 9,557 Income (loss) before income taxes 591 (733 ) 1,319 497 (608 ) 1,066 Provision (benefit) for income taxes (68 ) (270 ) 478 149 — 289 Net income (loss) 659 (463 ) 841 348 (608 ) 777 Net income attributable to noncontrolling interests — — 23 95 — 118 Net income (loss) attributable to HCA Healthcare, Inc. $ 659 $ (463 ) $ 818 $ 253 $ (608 ) $ 659 Comprehensive income (loss) attributable to HCA Healthcare, Inc. $ 677 $ (456 ) $ 821 $ 261 $ (626 ) $ 677 HCA HEALTHCARE, INC. CONDENSED CONSOLIDATING COMPREHENSIVE INCOME STATEMENT FOR THE QUARTER ENDED MARCH 31, 2016 (Dollars in millions) HCA HCA Inc. Subsidiary Subsidiary Eliminations Condensed Revenues before provision for doubtful accounts $ — $ — $ 5,673 $ 5,377 $ — $ 11,050 Provision for doubtful accounts — — 494 296 — 790 Revenues — — 5,179 5,081 — 10,260 Salaries and benefits — — 2,354 2,348 — 4,702 Supplies — — 898 816 — 1,714 Other operating expenses 2 — 857 994 — 1,853 Equity in earnings of affiliates (629 ) — (2 ) (10 ) 629 (12 ) Depreciation and amortization — — 227 252 — 479 Interest expense 16 650 (207 ) (43 ) — 416 Losses (gains) on sales of facilities — — 2 (1 ) — 1 Legal claim costs — 12 — — — 12 Management fees — — (160 ) 160 — — (611 ) 662 3,969 4,516 629 9,165 Income (loss) before income taxes 611 (662 ) 1,210 565 (629 ) 1,095 Provision (benefit) for income taxes (83 ) (244 ) 438 173 — 284 Net income (loss) 694 (418 ) 772 392 (629 ) 811 Net income attributable to noncontrolling interests — — 22 95 — 117 Net income (loss) attributable to HCA Healthcare, Inc. $ 694 $ (418 ) $ 750 $ 297 $ (629 ) $ 694 Comprehensive income (loss) attributable to HCA Healthcare, Inc. $ 665 $ (425 ) $ 752 $ 273 $ (600 ) $ 665 HCA HEALTHCARE, INC. CONDENSED CONSOLIDATING BALANCE SHEET MARCH 31, 2017 (Dollars in millions) HCA HCA Inc. Subsidiary Subsidiary Eliminations Condensed ASSETS Current assets: Cash and cash equivalents $ — $ — $ 182 $ 571 $ — $ 753 Accounts receivable, net — — 3,009 2,655 — 5,664 Inventories — — 890 611 — 1,501 Other — — 432 687 — 1,119 — — 4,513 4,524 — 9,037 Property and equipment, net — — 8,446 8,016 — 16,462 Investments of insurance subsidiaries — — — 349 — 349 Investments in and advances to affiliates 27,671 — 16 178 (27,671 ) 194 Goodwill and other intangible assets — — 1,728 5,026 — 6,754 Other 756 37 33 173 — 999 $ 28,427 $ 37 $ 14,736 $ 18,266 $ (27,671 ) $ 33,795 LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY Current liabilities: Accounts payable $ — $ — $ 1,304 $ 929 $ — $ 2,233 Accrued salaries — — 644 506 — 1,150 Other accrued expenses 239 277 432 920 — 1,868 Long-term debt due within one year — 97 58 57 — 212 239 374 2,438 2,412 — 5,463 Long-term debt, net 993 29,841 188 280 — 31,302 Intercompany balances 33,807 (9,633 ) (26,980 ) 2,806 — — Professional liability risks — — — 1,134 — 1,134 Income taxes and other liabilities 405 8 395 445 — 1,253 35,444 20,590 (23,959) 7,077 — 39,152 Stockholders’ (deficit) equity attributable to HCA Healthcare, Inc. (7,017 ) (20,553 ) 38,573 9,651 (27,671 ) (7,017 ) Noncontrolling interests — — 122 1,538 — 1,660 (7,017 ) (20,553 ) 38,695 11,189 (27,671 ) (5,357 ) $ 28,427 $ 37 $ 14,736 $ 18,266 $ (27,671 ) $ 33,795 HCA HEALTHCARE, INC. CONDENSED CONSOLIDATING BALANCE SHEET DECEMBER 31, 2016 (Dollars in millions) HCA HCA Inc. Subsidiary Subsidiary Eliminations Condensed ASSETS Current assets: Cash and cash equivalents $ — $ — $ 110 $ 536 $ — $ 646 Accounts receivable, net — — 3,028 2,798 — 5,826 Inventories — — 890 613 — 1,503 Other — — 445 666 — 1,111 — — 4,473 4,613 — 9,086 Property and equipment, net — — 8,463 7,889 — 16,352 Investments of insurance subsidiaries — — — 336 — 336 Investments in and advances to affiliates 27,045 — 16 190 (27,045 ) 206 Goodwill and other intangible assets — — 1,728 4,976 — 6,704 Other 877 — 34 163 — 1,074 $ 27,922 $ — $ 14,714 $ 18,167 $ (27,045 ) $ 33,758 LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY Current liabilities: Accounts payable $ — $ — $ 1,439 $ 879 $ — $ 2,318 Accrued salaries — — 704 561 — 1,265 Other accrued expenses 29 572 464 970 — 2,035 Long-term debt due within one year — 97 60 59 — 216 29 669 2,667 2,469 — 5,834 Long-term debt, net 993 29,693 199 275 — 31,160 Intercompany balances 33,784 (10,277 ) (26,447 ) 2,940 — — Professional liability risks — — — 1,148 — 1,148 Income taxes and other liabilities 418 12 387 432 — 1,249 35,224 20,097 (23,194 ) 7,264 — 39,391 Stockholders’ (deficit) equity attributable to HCA Healthcare, Inc. (7,302 ) (20,097 ) 37,752 9,390 (27,045 ) (7,302 ) Noncontrolling interests — — 156 1,513 — 1,669 (7,302 ) (20,097 ) 37,908 10,903 (27,045 ) (5,633 ) $ 27,922 $ — $ 14,714 $ 18,167 $ (27,045 ) $ 33,758 HCA HEALTHCARE, INC. CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS FOR THE QUARTER ENDED MARCH 31, 2017 (Dollars in millions) HCA HCA Inc. Subsidiary Subsidiary Eliminations Condensed Cash flows from operating activities: Net income (loss) $ 659 $ (463 ) $ 841 $ 348 $ (608 ) $ 777 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Changes in operating assets and liabilities (15 ) (295 ) (601 ) (269 ) — (1,180 ) Provision for doubtful accounts — — 419 341 — 760 Depreciation and amortization — — 251 270 — 521 Income taxes 292 — — — — 292 Gains on sales of facilities — — — (1 ) — (1 ) Amortization of debt issuance costs — 8 — — — 8 Share-based compensation — — 73 — — 73 Equity in earnings of affiliates (608 ) — — — 608 — Other 19 — — 11 — 30 Net cash provided by (used in) operating activities 347 (750 ) 983 700 — 1,280 Cash flows from investing activities: Purchase of property and equipment — — (229 ) (342 ) — (571 ) Acquisition of hospitals and health care entities — — (5 ) (85 ) — (90 ) Disposition of hospitals and health care entities — — 4 — — 4 Change in investments — — — (19 ) — (19 ) Other — — — 7 — 7 Net cash used in investing activities — — (230 ) (439 ) — (669 ) Cash flows from financing activities: Net change in revolving credit facilities — 160 — — — 160 Repayment of long-term debt — (18 ) (16 ) (9 ) — (43 ) Distributions to noncontrolling interests — — (57 ) (88 ) — (145 ) Payment of debt issuance costs — (2 ) — — — (2 ) Repurchases of common stock (424 ) — — — — (424 ) Changes in intercompany balances with affiliates, net 134 610 (608 ) (136 ) — — Other (57 ) — — 7 — (50 ) Net cash (used in) provided by financing activities (347 ) 750 (681 ) (226 ) — (504 ) Change in cash and cash equivalents — — 72 35 — 107 Cash and cash equivalents at beginning of period — — 110 536 — 646 Cash and cash equivalents at end of period $ — $ — $ 182 $ 571 $ — $ 753 HCA HEALTHCARE, INC. CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS FOR THE QUARTER ENDED MARCH 31, 2016 (Dollars in millions) HCA HCA Inc. Subsidiary Subsidiary Eliminations Condensed Cash flows from operating activities: Net income (loss) $ 694 $ (418 ) $ 772 $ 392 $ (629 ) $ 811 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Changes in operating assets and liabilities (36 ) (67 ) (740 ) (303 ) — (1,146 ) Provision for doubtful accounts — — 494 296 — 790 Depreciation and amortization — — 227 252 — 479 Income taxes 360 — — — — 360 Losses (gains) on sales of facilities — — 2 (1 ) — 1 Legal claim costs — 12 — — — 12 Amortization of debt issuance costs — 10 — — — 10 Share-based compensation — — 65 — — 65 Equity in earnings of affiliates (629 ) — — — 629 — Other 19 — (4 ) 2 — 17 Net cash provided by (used in) operating activities 408 (463 ) 816 638 — 1,399 Cash flows from investing activities: Purchase of property and equipment — — (161 ) (348 ) — (509 ) Acquisition of hospitals and health care entities — — — (9 ) — (9 ) Disposition of hospitals and health care entities — — — 4 — 4 Change in investments — — — 11 — 11 Other — — — 7 — 7 Net cash used in investing activities — — (161 ) (335 ) — (496 ) Cash flows from financing activities: Issuance of long-term debt — 3,000 — — — 3,000 Net change in revolving credit facilities — (930 ) — — — (930 ) Repayment of long-term debt — (1,980 ) (17 ) (14 ) — (2,011 ) Distributions to noncontrolling interests — — (16 ) (95 ) — (111 ) Payment of debt issuance costs — (22 ) — — — (22 ) Repurchases of common stock (621 ) — — — — (621 ) Changes in intercompany balances with affiliates, net 311 395 (556 ) (150 ) — — Other (97 ) — — — — (97 ) Net cash (used in) provided by financing activities (407 ) 463 (589 ) (259 ) — (792 ) Change in cash and cash equivalents 1 — 66 44 — 111 Cash and cash equivalents at beginning of period — — 155 586 — 741 Cash and cash equivalents at end of period $ 1 $ — $ 221 $ 630 $ — $ 852

Basis of Presentation and Sig19

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2017
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal and recurring nature. The majority of our expenses are “costs of revenues” items. Costs that could be classified as general and administrative would include our corporate office costs, which were $90 million and $85 million for the quarters ended March 31, 2017 and 2016, respectively. Operating results for the quarter ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. For further information, refer to the consolidated financial statements and footnotes thereto included in our annual report on Form 10-K for the year ended December 31, 2016.
Revenues	Revenues Revenues are recorded during the period the health care services are provided, based upon the estimated amounts due from the patients and third-party payers. Third-party payers include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans and commercial insurance companies (including plans offered through the health insurance exchanges), and employers. Estimates of contractual allowances under managed care health plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record a provision for doubtful accounts (based primarily on historical collection experience) related to uninsured accounts to record net self pay revenues at the estimated amounts we expect to collect. Our revenues from third party payers, the uninsured and other for the quarters ended March 31, 2017 and 2016 are summarized in the following table (dollars in millions): 2017 Ratio 2016 Ratio Medicare $ 2,405 22.6 % $ 2,266 22.1 % Managed Medicare 1,203 11.3 1,104 10.8 Medicaid 373 3.5 427 4.2 Managed Medicaid 641 6.0 597 5.8 Managed care and other insurers 5,926 55.8 5,702 55.6 International (managed care and other insurers) 269 2.5 317 3.1 10,817 101.7 10,413 101.6 Uninsured 225 2.1 189 1.8 Other 341 3.2 448 4.4 Revenues before provision for doubtful accounts 11,383 107.0 11,050 107.8 Provision for doubtful accounts (760 ) (7.0 ) (790 ) (7.8 ) Revenues $ 10,623 100.0 % $ 10,260 100.0 %
Recent Pronouncements	Recent Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) and the International Accounting Standards Board issued a final, converged, principles-based standard on revenue recognition. Companies across all industries will use a five-step model to recognize revenue from customer contracts. The new standard, which replaces nearly all existing revenue recognition guidance, will require significant management judgments and change the way many companies recognize revenue in their financial statements. In July 2015, the FASB decided to defer the effective date of the new revenue standard by one year to annual and interim periods beginning after December 15, 2017 for public entities and permit entities to adopt one year earlier if they choose. The FASB decided, based on its outreach to various stakeholders and continuing amendments to the new revenue standard, that a deferral was necessary to provide adequate time to effectively implement the new standard. We are continuing to evaluate the effects the adoption of this standard will have on our financial statements and financial disclosures. We believe the most significant impact will be to the presentation of our income statement where the provision for doubtful accounts will be recorded as a direct reduction to revenues and will not be presented as a separate line item. We expect to adopt the new standard using the full retrospective application, and we do not believe the adoption will have a significant impact on our recognition of net revenues for any period. In February 2016, the FASB issued Accounting Standards Update 2016-02, Leases In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment In March 2017, the FASB issued ASU 2017-07, Compensation — Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform to the current year presentation.
Earning Per Share	We compute basic earnings per share using the weighted average number of common shares outstanding. We compute diluted earnings per share using the weighted average number of common shares outstanding, plus the dilutive effect of outstanding equity awards and potential shares, computed using the treasury stock method.
Fair Value Measurements and Disclosures	Accounting Standards Codification 820, Fair Value Measurements and Disclosures Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input significant to the fair value measurement in its entirety. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment.
Cash Traded Investments	Cash Traded Investments Our cash traded investments are generally classified within Level 1 or Level 2 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Certain types of cash traded instruments are classified within Level 3 of the fair value hierarchy because they trade infrequently and therefore have little or no price transparency. The valuation of these securities involves the consideration of market factors and management’s judgment.
Derivative Financial Instruments	Derivative Financial Instruments We have entered into interest rate swap agreements to manage our exposure to fluctuations in interest rates. The valuation of these instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. We incorporate credit valuation adjustments to reflect both our own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements of these instruments. Although we determined the majority of the inputs used to value our derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with our derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. We assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our derivative positions, and at March 31, 2017 and December 31, 2016, we determined the credit valuation adjustments were not significant to the overall valuation of our derivatives.
Interest Rate Swaps [Member]
Interest Rate Swap Agreements	Interest Rate Swap Agreements We have entered into interest rate swap agreements to manage our exposure to fluctuations in interest rates. These swap agreements involve the exchange of fixed and variable rate interest payments between two parties based on common notional principal amounts and maturity dates. Pay-fixed interest rate swaps effectively convert LIBOR indexed variable rate obligations to fixed interest rate obligations. The interest payments under these agreements are settled on a net basis. The net interest payments, based on the notional amounts in these agreements, generally match the timing of the related liabilities for the interest rate swap agreements which have been designated as cash flow hedges. The notional amounts of the swap agreements represent amounts used to calculate the exchange of cash flows and are not our assets or liabilities. Our credit risk related to these agreements is considered low because the swap agreements are with creditworthy financial institutions.

Basis of Presentation and Sig20

Basis of Presentation and Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Schedule of Revenues from Third Party Payers, Uninsured and Other Payers	Our revenues from third party payers, the uninsured and other for the quarters ended March 31, 2017 and 2016 are summarized in the following table (dollars in millions): 2017 Ratio 2016 Ratio Medicare $ 2,405 22.6 % $ 2,266 22.1 % Managed Medicare 1,203 11.3 1,104 10.8 Medicaid 373 3.5 427 4.2 Managed Medicaid 641 6.0 597 5.8 Managed care and other insurers 5,926 55.8 5,702 55.6 International (managed care and other insurers) 269 2.5 317 3.1 10,817 101.7 10,413 101.6 Uninsured 225 2.1 189 1.8 Other 341 3.2 448 4.4 Revenues before provision for doubtful accounts 11,383 107.0 11,050 107.8 Provision for doubtful accounts (760 ) (7.0 ) (790 ) (7.8 ) Revenues $ 10,623 100.0 % $ 10,260 100.0 %

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Schedule of Computations of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share for the quarters ended March 31, 2017 and 2016 (dollars and shares in millions, except per share amounts): 2017 2016 Net income attributable to HCA Healthcare, Inc. $ 659 $ 694 Weighted average common shares outstanding 370.289 396.397 Effect of dilutive incremental shares 9.691 14.178 Shares used for diluted earnings per share 379.980 410.575 Earnings per share: Basic earnings per share $ 1.78 $ 1.75 Diluted earnings per share $ 1.74 $ 1.69

Investments of Insurance Subs22

Investments of Insurance Subsidiaries (Tables)	3 Months Ended
	Mar. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Schedule of Investments	A summary of our insurance subsidiaries’ investments at March 31, 2017 and December 31, 2016 follows (dollars in millions): March 31, 2017 Amortized Unrealized Fair Gains Losses Debt securities: States and municipalities $ 355 $11 $— $ 366 Money market funds 29 — — 29 384 11 — 395 Equity securities 1 3 — 4 $ 385 $14 $— 399 Amounts classified as current assets (50 ) Investment carrying value $ 349 December 31, 2016 Amortized Unrealized Fair Gains Losses Debt securities: States and municipalities $ 345 $9 $(1 ) $ 353 Money market funds 28 — — 28 373 9 (1 ) 381 Equity securities 1 3 — 4 $ 374 $12 $(1 ) 385 Amounts classified as current assets (49 ) Investment carrying value $ 336
Schedule of Maturities of Investments	Scheduled maturities of investments in debt securities at March 31, 2017 were as follows (dollars in millions): Amortized Fair Due in one year or less $ 98 $ 98 Due after one year through five years 78 81 Due after five years through ten years 164 172 Due after ten years 44 44 $ 384 $ 395

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Interest Rate Swap Agreements Designated as Cash Flow Hedges	The following table sets forth our interest rate swap agreements, which have been designated as cash flow hedges, at March 31, 2017 (dollars in millions): Notional Maturity Date Fair Pay-fixed interest rate swaps $ 1,000 December 2017 $ (8 ) Pay-fixed interest rate swaps 2,000 December 2021 37
Effect of Interest Rate on Results of Operations	The following table presents the effect of our interest rate swaps on our results of operations for the quarter ended March 31, 2017 (dollars in millions): Derivatives in Cash Flow Hedging Relationships Amount of Gain Location of Loss Amount of Loss Interest rate swaps $ 2 Interest expense $ 7

Assets and Liabilities Measur24

Assets and Liabilities Measured at Fair Value (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables summarize our assets and liabilities measured at fair value on a recurring basis as of March 31, 2017 and December 31, 2016, aggregated by the level in the fair value hierarchy within which those measurements fall (dollars in millions): March 31, 2017 Fair Value Fair Value Measurements Using Quoted Prices in Significant Other Significant Assets: Investments of insurance subsidiaries: Debt securities: States and municipalities $ 366 $ — $ 360 $ 6 Money market funds 29 29 — — 395 29 360 6 Equity securities 4 4 — — Investments of insurance subsidiaries 399 33 360 6 Less amounts classified as current assets (50 ) (29 ) (21 ) — $ 349 $ 4 $ 339 $ 6 Interest rate swaps (Other) $ 37 $ — $ 37 $ — Liabilities: Interest rate swaps (Income taxes and other liabilities) $ 8 $ — $ 8 $ — December 31, 2016 Fair Value Measurements Using Fair Value Quoted Prices in Significant Other Significant Assets: Investments of insurance subsidiaries: Debt securities: States and municipalities $ 353 $ — $ 347 $ 6 Money market funds 28 28 — — 381 28 347 6 Equity securities 4 4 — — Investments of insurance subsidiaries 385 32 347 6 Less amounts classified as current assets (49 ) (28 ) (21 ) — $ 336 $ 4 $ 326 $ 6 Interest rate swaps (Other) $ 31 $ — $ 31 $ — Liabilities: Interest rate swaps (Income taxes and other liabilities) $ 12 $ — $ 12 $ —

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	A summary of long-term debt at March 31, 2017 and December 31, 2016, including related interest rates at March 31, 2017, follows (dollars in millions): March 31, December 31, Senior secured asset-based revolving credit facility (effective interest rate of 2.4%) $ 3,080 $ 2,920 Senior secured revolving credit facility — — Senior secured term loan facilities (effective interest rate of 3.5%) 3,963 3,981 Senior secured notes (effective interest rate of 5.4%) 13,800 13,800 Other senior secured debt (effective interest rate of 5.8%) 584 593 Senior secured debt 21,427 21,294 Senior unsecured notes (effective interest rate of 6.5%) 10,252 10,252 Net debt issuance costs (165 ) (170 ) Total debt (average life of 6.1 years, rates averaging 5.2%) 31,514 31,376 Less amounts due within one year 212 216 $ 31,302 $ 31,160

Capital Structure (Tables)

Capital Structure (Tables)	3 Months Ended
	Mar. 31, 2017
Text Block [Abstract]
Schedule of Changes in Stockholders' Deficit and Equity	The changes in stockholders’ deficit, including changes in stockholders’ deficit attributable to HCA Healthcare, Inc. and changes in equity attributable to noncontrolling interests, are as follows (dollars and shares in millions): Equity (Deficit) Attributable to HCA Healthcare, Inc. Equity Total Common Stock Capital in Accumulated Retained Shares Par Value Balances at December 31, 2016 370.536 $ 4 $ — $ (338 ) $ (6,968 ) $ 1,669 $ (5,633 ) Comprehensive income — — — 18 659 118 795 Repurchase of common stock (5.121 ) — (32 ) — (392 ) — (424 ) Distributions — — — — — (145 ) (145 ) Share-based benefit plans 3.280 — 35 — — — 35 Other — — (3 ) — — 18 15 Balances at March 31, 2017 368.695 $ 4 $ — $ (320 ) $ (6,701 ) $ 1,660 $ (5,357 )
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive loss are as follows (dollars in millions): Unrealized Foreign Defined Change Total Balances at December 31, 2016 $ 7 $ (211 ) $ (146 ) $ 12 $ (338 ) Unrealized gains on available-for-sale securities, net of $1 of income taxes 2 — — — 2 Foreign currency translation adjustments, net of $4 of income taxes — 6 — — 6 Change in fair value of derivative instruments, net of $1 of income taxes — — — 2 2 Expense reclassified into operations from other comprehensive income, net of $2 and $2, respectively, income tax benefits — — 3 5 8 Balances at March 31, 2017 $ 9 $ (205 ) $ (143 ) $ 19 $ (320 )

Segment and Geographic Inform27

Segment and Geographic Information (Tables)	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Schedule of Geographic Distributions of Revenues, Equity in Earnings of Affiliates, Adjusted Segment EBITDA and Depreciation and Amortization	The geographic distributions of our revenues, equity in earnings of affiliates, adjusted segment EBITDA and depreciation and amortization for the quarters ended March 31, 2017 and 2016 are summarized in the following table (dollars in millions): 2017 2016 Revenues: National Group $ 5,148 $ 4,967 American Group 4,995 4,786 Corporate and other 480 507 $ 10,623 $ 10,260 Equity in earnings of affiliates: National Group $ (5 ) $ (2 ) American Group (8 ) (9 ) Corporate and other 3 (1 ) $ (10 ) $ (12 ) Adjusted segment EBITDA: National Group $ 1,131 $ 1,138 American Group 1,007 982 Corporate and other (133 ) (117 ) $ 2,005 $ 2,003 Depreciation and amortization: National Group $ 214 $ 197 American Group 238 219 Corporate and other 69 63 $ 521 $ 479 Adjusted segment EBITDA $ 2,005 $ 2,003 Depreciation and amortization 521 479 Interest expense 419 416 Losses (gains) on sales of facilities (1 ) 1 Legal claim costs — 12 Income before income taxes $ 1,066 $ 1,095

Supplemental Condensed Consol28

Supplemental Condensed Consolidating Financial Information (Tables)	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Condensed Consolidating Comprehensive Income Statement	HCA HEALTHCARE, INC. CONDENSED CONSOLIDATING COMPREHENSIVE INCOME STATEMENT FOR THE QUARTER ENDED MARCH 31, 2017 (Dollars in millions) HCA HCA Inc. Subsidiary Subsidiary Eliminations Condensed Revenues before provision for doubtful accounts $ — $ — $ 5,853 $ 5,530 $ — $ 11,383 Provision for doubtful accounts — — 419 341 — 760 Revenues — — 5,434 5,189 — 10,623 Salaries and benefits — — 2,466 2,435 — 4,901 Supplies — — 951 846 — 1,797 Other operating expenses 1 — 927 1,002 — 1,930 Equity in earnings of affiliates (608 ) — (1 ) (9 ) 608 (10 ) Depreciation and amortization — — 251 270 — 521 Interest expense 16 733 (269 ) (61 ) — 419 Gains on sales of facilities — — — (1 ) — (1 ) Management fees — — (210 ) 210 — — (591 ) 733 4,115 4,692 608 9,557 Income (loss) before income taxes 591 (733 ) 1,319 497 (608 ) 1,066 Provision (benefit) for income taxes (68 ) (270 ) 478 149 — 289 Net income (loss) 659 (463 ) 841 348 (608 ) 777 Net income attributable to noncontrolling interests — — 23 95 — 118 Net income (loss) attributable to HCA Healthcare, Inc. $ 659 $ (463 ) $ 818 $ 253 $ (608 ) $ 659 Comprehensive income (loss) attributable to HCA Healthcare, Inc. $ 677 $ (456 ) $ 821 $ 261 $ (626 ) $ 677 HCA HEALTHCARE, INC. CONDENSED CONSOLIDATING COMPREHENSIVE INCOME STATEMENT FOR THE QUARTER ENDED MARCH 31, 2016 (Dollars in millions) HCA HCA Inc. Subsidiary Subsidiary Eliminations Condensed Revenues before provision for doubtful accounts $ — $ — $ 5,673 $ 5,377 $ — $ 11,050 Provision for doubtful accounts — — 494 296 — 790 Revenues — — 5,179 5,081 — 10,260 Salaries and benefits — — 2,354 2,348 — 4,702 Supplies — — 898 816 — 1,714 Other operating expenses 2 — 857 994 — 1,853 Equity in earnings of affiliates (629 ) — (2 ) (10 ) 629 (12 ) Depreciation and amortization — — 227 252 — 479 Interest expense 16 650 (207 ) (43 ) — 416 Losses (gains) on sales of facilities — — 2 (1 ) — 1 Legal claim costs — 12 — — — 12 Management fees — — (160 ) 160 — — (611 ) 662 3,969 4,516 629 9,165 Income (loss) before income taxes 611 (662 ) 1,210 565 (629 ) 1,095 Provision (benefit) for income taxes (83 ) (244 ) 438 173 — 284 Net income (loss) 694 (418 ) 772 392 (629 ) 811 Net income attributable to noncontrolling interests — — 22 95 — 117 Net income (loss) attributable to HCA Healthcare, Inc. $ 694 $ (418 ) $ 750 $ 297 $ (629 ) $ 694 Comprehensive income (loss) attributable to HCA Healthcare, Inc. $ 665 $ (425 ) $ 752 $ 273 $ (600 ) $ 665
Schedule of Condensed Consolidating Balance Sheet	HCA HEALTHCARE, INC. CONDENSED CONSOLIDATING BALANCE SHEET MARCH 31, 2017 (Dollars in millions) HCA HCA Inc. Subsidiary Subsidiary Eliminations Condensed ASSETS Current assets: Cash and cash equivalents $ — $ — $ 182 $ 571 $ — $ 753 Accounts receivable, net — — 3,009 2,655 — 5,664 Inventories — — 890 611 — 1,501 Other — — 432 687 — 1,119 — — 4,513 4,524 — 9,037 Property and equipment, net — — 8,446 8,016 — 16,462 Investments of insurance subsidiaries — — — 349 — 349 Investments in and advances to affiliates 27,671 — 16 178 (27,671 ) 194 Goodwill and other intangible assets — — 1,728 5,026 — 6,754 Other 756 37 33 173 — 999 $ 28,427 $ 37 $ 14,736 $ 18,266 $ (27,671 ) $ 33,795 LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY Current liabilities: Accounts payable $ — $ — $ 1,304 $ 929 $ — $ 2,233 Accrued salaries — — 644 506 — 1,150 Other accrued expenses 239 277 432 920 — 1,868 Long-term debt due within one year — 97 58 57 — 212 239 374 2,438 2,412 — 5,463 Long-term debt, net 993 29,841 188 280 — 31,302 Intercompany balances 33,807 (9,633 ) (26,980 ) 2,806 — — Professional liability risks — — — 1,134 — 1,134 Income taxes and other liabilities 405 8 395 445 — 1,253 35,444 20,590 (23,959) 7,077 — 39,152 Stockholders’ (deficit) equity attributable to HCA Healthcare, Inc. (7,017 ) (20,553 ) 38,573 9,651 (27,671 ) (7,017 ) Noncontrolling interests — — 122 1,538 — 1,660 (7,017 ) (20,553 ) 38,695 11,189 (27,671 ) (5,357 ) $ 28,427 $ 37 $ 14,736 $ 18,266 $ (27,671 ) $ 33,795 HCA HEALTHCARE, INC. CONDENSED CONSOLIDATING BALANCE SHEET DECEMBER 31, 2016 (Dollars in millions) HCA HCA Inc. Subsidiary Subsidiary Eliminations Condensed ASSETS Current assets: Cash and cash equivalents $ — $ — $ 110 $ 536 $ — $ 646 Accounts receivable, net — — 3,028 2,798 — 5,826 Inventories — — 890 613 — 1,503 Other — — 445 666 — 1,111 — — 4,473 4,613 — 9,086 Property and equipment, net — — 8,463 7,889 — 16,352 Investments of insurance subsidiaries — — — 336 — 336 Investments in and advances to affiliates 27,045 — 16 190 (27,045 ) 206 Goodwill and other intangible assets — — 1,728 4,976 — 6,704 Other 877 — 34 163 — 1,074 $ 27,922 $ — $ 14,714 $ 18,167 $ (27,045 ) $ 33,758 LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY Current liabilities: Accounts payable $ — $ — $ 1,439 $ 879 $ — $ 2,318 Accrued salaries — — 704 561 — 1,265 Other accrued expenses 29 572 464 970 — 2,035 Long-term debt due within one year — 97 60 59 — 216 29 669 2,667 2,469 — 5,834 Long-term debt, net 993 29,693 199 275 — 31,160 Intercompany balances 33,784 (10,277 ) (26,447 ) 2,940 — — Professional liability risks — — — 1,148 — 1,148 Income taxes and other liabilities 418 12 387 432 — 1,249 35,224 20,097 (23,194 ) 7,264 — 39,391 Stockholders’ (deficit) equity attributable to HCA Healthcare, Inc. (7,302 ) (20,097 ) 37,752 9,390 (27,045 ) (7,302 ) Noncontrolling interests — — 156 1,513 — 1,669 (7,302 ) (20,097 ) 37,908 10,903 (27,045 ) (5,633 ) $ 27,922 $ — $ 14,714 $ 18,167 $ (27,045 ) $ 33,758
Schedule of Condensed Consolidating Statement of Cash Flows	HCA HEALTHCARE, INC. CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS FOR THE QUARTER ENDED MARCH 31, 2017 (Dollars in millions) HCA HCA Inc. Subsidiary Subsidiary Eliminations Condensed Cash flows from operating activities: Net income (loss) $ 659 $ (463 ) $ 841 $ 348 $ (608 ) $ 777 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Changes in operating assets and liabilities (15 ) (295 ) (601 ) (269 ) — (1,180 ) Provision for doubtful accounts — — 419 341 — 760 Depreciation and amortization — — 251 270 — 521 Income taxes 292 — — — — 292 Gains on sales of facilities — — — (1 ) — (1 ) Amortization of debt issuance costs — 8 — — — 8 Share-based compensation — — 73 — — 73 Equity in earnings of affiliates (608 ) — — — 608 — Other 19 — — 11 — 30 Net cash provided by (used in) operating activities 347 (750 ) 983 700 — 1,280 Cash flows from investing activities: Purchase of property and equipment — — (229 ) (342 ) — (571 ) Acquisition of hospitals and health care entities — — (5 ) (85 ) — (90 ) Disposition of hospitals and health care entities — — 4 — — 4 Change in investments — — — (19 ) — (19 ) Other — — — 7 — 7 Net cash used in investing activities — — (230 ) (439 ) — (669 ) Cash flows from financing activities: Net change in revolving credit facilities — 160 — — — 160 Repayment of long-term debt — (18 ) (16 ) (9 ) — (43 ) Distributions to noncontrolling interests — — (57 ) (88 ) — (145 ) Payment of debt issuance costs — (2 ) — — — (2 ) Repurchases of common stock (424 ) — — — — (424 ) Changes in intercompany balances with affiliates, net 134 610 (608 ) (136 ) — — Other (57 ) — — 7 — (50 ) Net cash (used in) provided by financing activities (347 ) 750 (681 ) (226 ) — (504 ) Change in cash and cash equivalents — — 72 35 — 107 Cash and cash equivalents at beginning of period — — 110 536 — 646 Cash and cash equivalents at end of period $ — $ — $ 182 $ 571 $ — $ 753 HCA HEALTHCARE, INC. CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS FOR THE QUARTER ENDED MARCH 31, 2016 (Dollars in millions) HCA HCA Inc. Subsidiary Subsidiary Eliminations Condensed Cash flows from operating activities: Net income (loss) $ 694 $ (418 ) $ 772 $ 392 $ (629 ) $ 811 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Changes in operating assets and liabilities (36 ) (67 ) (740 ) (303 ) — (1,146 ) Provision for doubtful accounts — — 494 296 — 790 Depreciation and amortization — — 227 252 — 479 Income taxes 360 — — — — 360 Losses (gains) on sales of facilities — — 2 (1 ) — 1 Legal claim costs — 12 — — — 12 Amortization of debt issuance costs — 10 — — — 10 Share-based compensation — — 65 — — 65 Equity in earnings of affiliates (629 ) — — — 629 — Other 19 — (4 ) 2 — 17 Net cash provided by (used in) operating activities 408 (463 ) 816 638 — 1,399 Cash flows from investing activities: Purchase of property and equipment — — (161 ) (348 ) — (509 ) Acquisition of hospitals and health care entities — — — (9 ) — (9 ) Disposition of hospitals and health care entities — — — 4 — 4 Change in investments — — — 11 — 11 Other — — — 7 — 7 Net cash used in investing activities — — (161 ) (335 ) — (496 ) Cash flows from financing activities: Issuance of long-term debt — 3,000 — — — 3,000 Net change in revolving credit facilities — (930 ) — — — (930 ) Repayment of long-term debt — (1,980 ) (17 ) (14 ) — (2,011 ) Distributions to noncontrolling interests — — (16 ) (95 ) — (111 ) Payment of debt issuance costs — (22 ) — — — (22 ) Repurchases of common stock (621 ) — — — — (621 ) Changes in intercompany balances with affiliates, net 311 395 (556 ) (150 ) — — Other (97 ) — — — — (97 ) Net cash (used in) provided by financing activities (407 ) 463 (589 ) (259 ) — (792 ) Change in cash and cash equivalents 1 — 66 44 — 111 Cash and cash equivalents at beginning of period — — 155 586 — 741 Cash and cash equivalents at end of period $ 1 $ — $ 221 $ 630 $ — $ 852

Basis of Presentation and Sig29

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2017USD ($)HospitalStateSurgery_Center	Mar. 31, 2016USD ($)
Accounting Policies [Abstract]
Number of owned and operated hospitals | Hospital	171
Number of freestanding surgery centers | Surgery_Center	118
Number of facilities locations | State	20
General and administrative expense | $	$ 90	$ 85

Basis of Presentation and Sig30

Basis of Presentation and Significant Accounting Policies - Schedule of Revenues from Third Party Payers, Uninsured and Other Payers (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues From Third Party Payers [Line Items]
Revenues from third party payers	$ 10,817	$ 10,413
Uninsured	225	189
Other	341	448
Revenues before provision for doubtful accounts	11,383	11,050
Provision for doubtful accounts	(760)	(790)
Revenues	$ 10,623	$ 10,260
Revenues from third party payers, Ratio	101.70%	101.60%
Uninsured, Ratio	2.10%	1.80%
Other, Ratio	3.20%	4.40%
Revenues before provision for doubtful accounts, Ratio	107.00%	107.80%
Provision for doubtful accounts, Ratio	(7.00%)	(7.80%)
Revenues ratio from third party payers	100.00%	100.00%
Medicare [Member]
Revenues From Third Party Payers [Line Items]
Revenues from third party payers	$ 2,405	$ 2,266
Revenues from third party payers, Ratio	22.60%	22.10%
Managed Medicare [Member]
Revenues From Third Party Payers [Line Items]
Revenues from third party payers	$ 1,203	$ 1,104
Revenues from third party payers, Ratio	11.30%	10.80%
Medicaid [Member]
Revenues From Third Party Payers [Line Items]
Revenues from third party payers	$ 373	$ 427
Revenues from third party payers, Ratio	3.50%	4.20%
Managed Medicaid [Member]
Revenues From Third Party Payers [Line Items]
Revenues from third party payers	$ 641	$ 597
Revenues from third party payers, Ratio	6.00%	5.80%
Managed Care and Other Insurers [Member]
Revenues From Third Party Payers [Line Items]
Revenues from third party payers	$ 5,926	$ 5,702
Revenues from third party payers, Ratio	55.80%	55.60%
International (Managed Care and Other Insurers) [Member]
Revenues From Third Party Payers [Line Items]
Revenues from third party payers	$ 269	$ 317
Revenues from third party payers, Ratio	2.50%	3.10%

Acquisitions and Dispositions -

Acquisitions and Dispositions - Additional Information (Detail) $ in Millions	1 Months Ended	3 Months Ended
	May 09, 2017USD ($)Hospital	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)
Business Acquisition [Line Items]
Proceeds from sale of business		$ 4	$ 4
Subsequent Event [Member]
Business Acquisition [Line Items]
Number of hospitals purchased | Hospital	6
Nonhospital Health Care [Member]
Business Acquisition [Line Items]
Aggregate purchase price		90	9
Hospitals [Member] | Subsequent Event [Member]
Business Acquisition [Line Items]
Aggregate purchase price	$ 950
Real Estate and Other Investments [Member]
Business Acquisition [Line Items]
Proceeds from sale of business		4	4
Pretax gain (loss) on sales of business		$ 1	$ 1

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Liability for unrecognized tax benefits	$ 405		$ 418
Unrecognized tax benefits, accrued interest	42		45
Unrecognized tax benefits that would impact effective tax rate	134		$ 137
Provision for tax benefits related to settlement of employee awards	$ 67	$ 74

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Computations of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Earnings Per Share [Abstract]
Net income attributable to HCA Healthcare, Inc.	$ 659	$ 694
Weighted average common shares outstanding	370,289	396,397
Effect of dilutive incremental shares	9,691	14,178
Shares used for diluted earnings per share	379,980	410,575
Basic earnings per share	$ 1.78	$ 1.75
Diluted earnings per share	$ 1.74	$ 1.69

Investments of Insurance Subs34

Investments of Insurance Subsidiaries - Schedule of Investments (Detail) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 385	$ 374
Unrealized Amounts, Gains	14	12
Unrealized Amounts, Losses		(1)
Fair Value	399	385
Amounts classified as current assets	(50)	(49)
Investment carrying value	349	336
Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	384	373
Unrealized Amounts, Gains	11	9
Unrealized Amounts, Losses		(1)
Fair Value	395	381
Debt Securities [Member] | States and Municipalities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	355	345
Unrealized Amounts, Gains	11	9
Unrealized Amounts, Losses		(1)
Fair Value	366	353
Debt Securities [Member] | Money Market Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	29	28
Fair Value	29	28
Equity Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1	1
Unrealized Amounts, Gains	3	3
Fair Value	$ 4	$ 4

Investments of Insurance Subs35

Investments of Insurance Subsidiaries - Schedule of Maturities of Investments (Detail) $ in Millions	Mar. 31, 2017USD ($)
Investments, Debt and Equity Securities [Abstract]
Due in one year or less, Amortized Cost	$ 98
Due after one year through five years, Amortized Cost	78
Due after five years through ten years, Amortized Cost	164
Due after ten years, Amortized Cost	44
Amortized Cost, Total	384
Due in one year or less, Fair Value	98
Due after one year through five years, Fair Value	81
Due after five years through ten years, Fair Value	172
Due after ten years, Fair Value	44
Fair Value, Total	$ 395

Investments of Insurance Subs36

Investments of Insurance Subsidiaries - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Available for sale securities expected maturity of debt securities	3 years 10 months 24 days
Available for sale securities average scheduled maturity	5 years 7 months 6 days

Financial Instruments - Schedul

Financial Instruments - Schedule of Interest Rate Swap Agreements Designated as Cash Flow Hedges (Detail) - Pay-Fixed Interest Rate Swaps [Member]	3 Months Ended
	Mar. 31, 2017USD ($)
Maturity Date, 2017 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	$ 1,000,000,000
Fair Value	$ (8,000,000)
Maturity Date	Dec. 31, 2017
Maturity Date, 2021 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	$ 2,000,000,000
Fair Value	$ 37,000,000
Maturity Date	Dec. 31, 2021

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Estimated amount reclassified from other comprehensive income to interest expense	$ 13

Financial Instruments - Effect

Financial Instruments - Effect of Interest Rate Swaps on Results of Operations (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Derivative Instruments, Gain (Loss) [Line Items]
Interest expense	$ 419	$ 416
Interest Rate Swaps [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Recognized in OCI on Derivatives, Net of Tax	2
Reclassification out of Accumulated Other Comprehensive Income [Member] | Interest Rate Swaps [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest expense	$ 7

Assets and Liabilities Measur40

Assets and Liabilities Measured at Fair Value - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	$ 399	$ 385
Less amounts classified as current assets	(50)	(49)
Investments of insurance subsidiaries, noncurrent	349	336
Interest Rate Swaps [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Interest rate swaps (Other)	37	31
Liabilities, Fair Value	8	12
Debt Securities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	395	381
Debt Securities [Member] | States and Municipalities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	366	353
Debt Securities [Member] | Money Market Funds [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	29	28
Equity Securities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	4	4
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	33	32
Less amounts classified as current assets	(29)	(28)
Investments of insurance subsidiaries, noncurrent	4	4
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) [Member] | Debt Securities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	29	28
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) [Member] | Debt Securities [Member] | Money Market Funds [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	29	28
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) [Member] | Equity Securities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	4	4
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	360	347
Less amounts classified as current assets	(21)	(21)
Investments of insurance subsidiaries, noncurrent	339	326
Significant Other Observable Inputs (Level 2) [Member] | Interest Rate Swaps [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Interest rate swaps (Other)	37	31
Liabilities, Fair Value	8	12
Significant Other Observable Inputs (Level 2) [Member] | Debt Securities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	360	347
Significant Other Observable Inputs (Level 2) [Member] | Debt Securities [Member] | States and Municipalities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	360	347
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	6	6
Investments of insurance subsidiaries, noncurrent	6	6
Significant Unobservable Inputs (Level 3) [Member] | Debt Securities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	6	6
Significant Unobservable Inputs (Level 3) [Member] | Debt Securities [Member] | States and Municipalities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	$ 6	$ 6

Assets and Liabilities Measur41

Assets and Liabilities Measured at Fair Value - Additional Information (Detail) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Estimated fair value of long-term debt	$ 33,267	$ 32,833
Carrying amounts of long-term debt	$ 31,679	$ 31,546

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-Term Debt (Detail) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Senior secured debt	$ 21,427	$ 21,294
Net debt issuance costs	(165)	(170)
Total debt (average life of 6.1 years, rates averaging 5.2%)	31,514	31,376
Less amounts due within one year	212	216
Long-term debt	31,302	31,160
Senior Secured Asset-Based Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Long-term line of credit	3,080	2,920
Senior Secured Term Loan Facilities [Member]
Debt Instrument [Line Items]
Senior secured debt	3,963	3,981
Senior Secured Notes [Member]
Debt Instrument [Line Items]
Senior secured debt	13,800	13,800
Other Senior Secured Debt [Member]
Debt Instrument [Line Items]
Other senior secured debt	584	593
Senior Unsecured Notes [Member]
Debt Instrument [Line Items]
Senior unsecured notes	$ 10,252	$ 10,252

Long-Term Debt - Schedule of 43

Long-Term Debt - Schedule of Long-Term Debt (Parenthetical) (Detail)	3 Months Ended
	Mar. 31, 2017
Debt Instrument [Line Items]
Total debt average term	6 years 1 month 6 days
Total debt average rate	5.20%
Senior Secured Asset-Based Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Effective interest rate	2.40%
Senior Secured Term Loan Facilities [Member]
Debt Instrument [Line Items]
Effective interest rate	3.50%
Senior Secured Notes [Member]
Debt Instrument [Line Items]
Effective interest rate	5.40%
Other Senior Secured Debt [Member]
Debt Instrument [Line Items]
Effective interest rate	5.80%
Senior Unsecured Notes [Member]
Debt Instrument [Line Items]
Effective interest rate	6.50%

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) - Senior Notes [Member] - USD ($)	1 Months Ended
	Aug. 31, 2016	Mar. 31, 2016
Debt Instrument [Line Items]
Debt instrument maturity date	Feb. 29, 2024	Mar. 31, 2023
Senior Secured Notes Due 2026 [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount		$ 1,500,000,000
Debt instrument, stated interest		5.25%
Senior Secured Notes Due 2023 [Member]
Debt Instrument [Line Items]
Proceeds from new term loan		$ 1,500,000,000
Senior Secured Notes Due 2027 [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount	$ 1,200,000,000
Debt instrument, stated interest	4.50%
Senior Secured Notes Due 2024 [Member]
Debt Instrument [Line Items]
Proceeds from new term loan	$ 1,200,000,000

Capital Structure - Schedule of

Capital Structure - Schedule of Changes in Stockholders' Deficit and Equity (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Capital Structure [Line Items]
Beginning Balances	$ (5,633)
Comprehensive income	795	$ 782
Repurchase of common stock	(424)
Distributions	(145)
Share-based benefit plans	35
Other	15
Ending Balances	(5,357)
Common Stock [Member]
Capital Structure [Line Items]
Beginning Balances	4
Ending Balances	$ 4
Beginning Balances, Shares	370,536,000
Repurchase of common stock, shares	(5,121,000)
Share-based benefit plans, Shares	3,280,000
Ending Balances, Shares	368,695,000
Capital in Excess of Par Value [Member]
Capital Structure [Line Items]
Repurchase of common stock	$ (32)
Share-based benefit plans	35
Other	(3)
Accumulated Other Comprehensive Loss [Member]
Capital Structure [Line Items]
Beginning Balances	(338)
Comprehensive income	18
Ending Balances	(320)
Retained Deficit [Member]
Capital Structure [Line Items]
Beginning Balances	(6,968)
Comprehensive income	659
Repurchase of common stock	(392)
Ending Balances	(6,701)
Equity Attributable to Noncontrolling Interests [Member]
Capital Structure [Line Items]
Beginning Balances	1,669
Comprehensive income	118
Distributions	(145)
Other	18
Ending Balances	$ 1,660

Capital Structure - Additional

Capital Structure - Additional Information (Detail) - Common Stock [Member] - USD ($)	3 Months Ended
	Mar. 31, 2017	Nov. 30, 2016
Capital Structure [Line Items]
Repurchase of common stock, shares	(5,121,000)
Repurchase price of common stock, per share	$ 82.83
Share repurchase program, remaining authorized repurchase amount	$ 1,429,000,000
Share repurchase program authorized amount		$ 2,000,000,000

Capital Structure - Components

Capital Structure - Components of Accumulated Other Comprehensive Loss (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2017USD ($)
Equity [Abstract]
Unrealized gains on available-for-sale securities, beginning balances	$ 7
Unrealized gains on available-for-sale securities, net of income taxes	2
Unrealized gains on available-for-sale securities, ending balances	9
Foreign currency translation adjustments, beginning balances	(211)
Foreign currency translation adjustments	6
Foreign currency translation adjustments, ending balances	(205)
Defined benefit plans, beginning balances	(146)
Defined benefit plans, (income) expense reclassified into operations from other comprehensive income	3
Defined benefit plans, ending balances	(143)
Change in fair value of derivative instruments, beginning balances	12
Change in fair value of derivative instruments net of income taxes	2
Change in fair value of derivatives instruments, (income) expense reclassified into operations from other comprehensive income	5
Change in fair value of derivative instruments, ending balances	19
Accumulated other comprehensive income, net of tax, beginning balances	(338)
Unrealized gains on available-for-sale securities, net of income taxes	2
Foreign currency translation adjustments	6
Change in fair value of derivative instruments	2
Expense reclassified into operations from other comprehensive income, Total	8
Accumulated other comprehensive income (loss), net of tax, ending balances	$ (320)

Capital Structure - Component48

Capital Structure - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2017USD ($)
Equity [Abstract]
Unrealized gains on available-for-sale securities, tax portion	$ 1
Foreign currency translation adjustments, income taxes	4
Defined benefit plans, Expense reclassified into operations from other comprehensive income, Income tax benefits	2
Change in fair value of derivative instruments, change in fair value of derivative instruments, income taxes	1
Change in fair value of derivative instruments, Expense reclassified into operations from other comprehensive income, income tax benefits	$ 2

Segment and Geographic Inform49

Segment and Geographic Information - Additional Information (Detail) - Hospital	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Number of geographically organized groups	2
Number of owned and operated hospitals	171
Reorganization Group [Member] | National Group [Member]
Segment Reporting Information [Line Items]
Number of owned and operated hospitals		85
Reorganization Group [Member] | American Group [Member]
Segment Reporting Information [Line Items]
Number of owned and operated hospitals		80
Reorganization Group [Member] | Corporate and Other [Member]
Segment Reporting Information [Line Items]
Number of owned and operated hospitals		6

Segment and Geographic Inform50

Segment and Geographic Information - Schedule of Geographic Distributions of Revenues, Equity in Earnings of Affiliates, Adjusted Segment EBITDA, Depreciation and Amortization and Assets (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information [Line Items]
Revenues	$ 10,623	$ 10,260
Equity in earnings of affiliates	10	12
Adjusted segment EBITDA	2,005	2,003
Depreciation and amortization	521	479
Interest expense	419	416
Losses (gains) on sales of facilities	(1)	1
Legal claim costs		12
Income before income taxes	1,066	1,095
National Group [Member]
Segment Reporting Information [Line Items]
Revenues	5,148	4,967
Equity in earnings of affiliates	(5)	(2)
Adjusted segment EBITDA	1,131	1,138
Depreciation and amortization	214	197
American Group [Member]
Segment Reporting Information [Line Items]
Revenues	4,995	4,786
Equity in earnings of affiliates	(8)	(9)
Adjusted segment EBITDA	1,007	982
Depreciation and amortization	238	219
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Revenues	480	507
Equity in earnings of affiliates	3	(1)
Adjusted segment EBITDA	(133)	(117)
Depreciation and amortization	$ 69	$ 63

Supplemental Condensed Consol51

Supplemental Condensed Consolidating Financial Information and Other Collateral-Related Information - Additional Information (Detail) - USD ($)	Mar. 31, 2017	Dec. 31, 2012
Supplemental Condensed Consolidating Financial Information [Line Items]
Ownership percentage held by parent	100.00%
Senior Unsecured Notes Due 2021 [Member]
Supplemental Condensed Consolidating Financial Information [Line Items]
Debt instrument, principal amount		$ 1,000,000,000
Debt instrument, stated interest		6.25%

Supplemental Condensed Consol52

Supplemental Condensed Consolidating Financial Information and Other Collateral-Related Information - Schedule of Condensed Consolidating Comprehensive Income Statement (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Condensed Statement of Income Captions [Line Items]
Revenues before provision for doubtful accounts	$ 11,383	$ 11,050
Provision for doubtful accounts	760	790
Revenues	10,623	10,260
Salaries and benefits	4,901	4,702
Supplies	1,797	1,714
Other operating expenses	1,930	1,853
Equity in earnings of affiliates	(10)	(12)
Depreciation and amortization	521	479
Interest expense	419	416
Gains on sales of facilities	(1)	1
Legal claim costs (benefits)		12
Total expenses including equity in earnings of affiliates	9,557	9,165
Income (loss) before income taxes	1,066	1,095
Provision (benefit) for income taxes	289	284
Net income (loss)	777	811
Net income attributable to noncontrolling interests	118	117
Net income (loss) attributable to HCA Healthcare, Inc.	659	694
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	677	665
HCA Healthcare, Inc. Issuer [Member]
Condensed Statement of Income Captions [Line Items]
Other operating expenses	1	2
Equity in earnings of affiliates	(608)	(629)
Interest expense	16	16
Total expenses including equity in earnings of affiliates	(591)	(611)
Income (loss) before income taxes	591	611
Provision (benefit) for income taxes	(68)	(83)
Net income (loss)	659	694
Net income (loss) attributable to HCA Healthcare, Inc.	659	694
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	677	665
HCA Inc. Issuer [Member]
Condensed Statement of Income Captions [Line Items]
Interest expense	733	650
Legal claim costs (benefits)		12
Total expenses including equity in earnings of affiliates	733	662
Income (loss) before income taxes	(733)	(662)
Provision (benefit) for income taxes	(270)	(244)
Net income (loss)	(463)	(418)
Net income (loss) attributable to HCA Healthcare, Inc.	(463)	(418)
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	(456)	(425)
Subsidiary Guarantors [Member]
Condensed Statement of Income Captions [Line Items]
Revenues before provision for doubtful accounts	5,853	5,673
Provision for doubtful accounts	419	494
Revenues	5,434	5,179
Salaries and benefits	2,466	2,354
Supplies	951	898
Other operating expenses	927	857
Equity in earnings of affiliates	(1)	(2)
Depreciation and amortization	251	227
Interest expense	(269)	(207)
Gains on sales of facilities		2
Management fees	(210)	(160)
Total expenses including equity in earnings of affiliates	4,115	3,969
Income (loss) before income taxes	1,319	1,210
Provision (benefit) for income taxes	478	438
Net income (loss)	841	772
Net income attributable to noncontrolling interests	23	22
Net income (loss) attributable to HCA Healthcare, Inc.	818	750
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	821	752
Subsidiary Non-Guarantors [Member]
Condensed Statement of Income Captions [Line Items]
Revenues before provision for doubtful accounts	5,530	5,377
Provision for doubtful accounts	341	296
Revenues	5,189	5,081
Salaries and benefits	2,435	2,348
Supplies	846	816
Other operating expenses	1,002	994
Equity in earnings of affiliates	(9)	(10)
Depreciation and amortization	270	252
Interest expense	(61)	(43)
Gains on sales of facilities	(1)	(1)
Management fees	210	160
Total expenses including equity in earnings of affiliates	4,692	4,516
Income (loss) before income taxes	497	565
Provision (benefit) for income taxes	149	173
Net income (loss)	348	392
Net income attributable to noncontrolling interests	95	95
Net income (loss) attributable to HCA Healthcare, Inc.	253	297
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	261	273
Eliminations [Member]
Condensed Statement of Income Captions [Line Items]
Equity in earnings of affiliates	608	629
Total expenses including equity in earnings of affiliates	608	629
Income (loss) before income taxes	(608)	(629)
Net income (loss)	(608)	(629)
Net income (loss) attributable to HCA Healthcare, Inc.	(608)	(629)
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	$ (626)	$ (600)

Supplemental Condensed Consol53

Supplemental Condensed Consolidating Financial Information and Other Collateral-Related Information - Schedule of Condensed Consolidating Balance Sheet (Detail) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 753	$ 646	$ 852	$ 741
Accounts receivable, net	5,664	5,826
Inventories	1,501	1,503
Other	1,119	1,111
Total current assets	9,037	9,086
Property and equipment, net	16,462	16,352
Investments of insurance subsidiaries	349	336
Investments in and advances to affiliates	194	206
Goodwill and other intangible assets	6,754	6,704
Other	999	1,074
Total assets	33,795	33,758
Current liabilities:
Accounts payable	2,233	2,318
Accrued salaries	1,150	1,265
Other accrued expenses	1,868	2,035
Long-term debt due within one year	212	216
Total current liabilities	5,463	5,834
Long-term debt, net	31,302	31,160
Professional liability risks	1,134	1,148
Income taxes and other liabilities	1,253	1,249
Total liabilities	39,152	39,391
Stockholders' (deficit) equity attributable to HCA Healthcare, Inc.	(7,017)	(7,302)
Noncontrolling interests	1,660	1,669
Total stockholders' deficit	(5,357)	(5,633)
Total liabilities and stockholders' deficit	33,795	33,758
HCA Healthcare, Inc. Issuer [Member]
Current assets:
Cash and cash equivalents			1	0
Investments in and advances to affiliates	27,671	27,045
Other	756	877
Total assets	28,427	27,922
Current liabilities:
Other accrued expenses	239	29
Total current liabilities	239	29
Long-term debt, net	993	993
Intercompany balances	33,807	33,784
Income taxes and other liabilities	405	418
Total liabilities	35,444	35,224
Stockholders' (deficit) equity attributable to HCA Healthcare, Inc.	(7,017)	(7,302)
Total stockholders' deficit	(7,017)	(7,302)
Total liabilities and stockholders' deficit	28,427	27,922
HCA Inc. Issuer [Member]
Current assets:
Other	37
Total assets	37
Current liabilities:
Other accrued expenses	277	572
Long-term debt due within one year	97	97
Total current liabilities	374	669
Long-term debt, net	29,841	29,693
Intercompany balances	(9,633)	(10,277)
Income taxes and other liabilities	8	12
Total liabilities	20,590	20,097
Stockholders' (deficit) equity attributable to HCA Healthcare, Inc.	(20,553)	(20,097)
Total stockholders' deficit	(20,553)	(20,097)
Total liabilities and stockholders' deficit	37
Subsidiary Guarantors [Member]
Current assets:
Cash and cash equivalents	182	110	221	155
Accounts receivable, net	3,009	3,028
Inventories	890	890
Other	432	445
Total current assets	4,513	4,473
Property and equipment, net	8,446	8,463
Investments in and advances to affiliates	16	16
Goodwill and other intangible assets	1,728	1,728
Other	33	34
Total assets	14,736	14,714
Current liabilities:
Accounts payable	1,304	1,439
Accrued salaries	644	704
Other accrued expenses	432	464
Long-term debt due within one year	58	60
Total current liabilities	2,438	2,667
Long-term debt, net	188	199
Intercompany balances	(26,980)	(26,447)
Income taxes and other liabilities	395	387
Total liabilities	(23,959)	(23,194)
Stockholders' (deficit) equity attributable to HCA Healthcare, Inc.	38,573	37,752
Noncontrolling interests	122	156
Total stockholders' deficit	38,695	37,908
Total liabilities and stockholders' deficit	14,736	14,714
Subsidiary Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	571	536	$ 630	$ 586
Accounts receivable, net	2,655	2,798
Inventories	611	613
Other	687	666
Total current assets	4,524	4,613
Property and equipment, net	8,016	7,889
Investments of insurance subsidiaries	349	336
Investments in and advances to affiliates	178	190
Goodwill and other intangible assets	5,026	4,976
Other	173	163
Total assets	18,266	18,167
Current liabilities:
Accounts payable	929	879
Accrued salaries	506	561
Other accrued expenses	920	970
Long-term debt due within one year	57	59
Total current liabilities	2,412	2,469
Long-term debt, net	280	275
Intercompany balances	2,806	2,940
Professional liability risks	1,134	1,148
Income taxes and other liabilities	445	432
Total liabilities	7,077	7,264
Stockholders' (deficit) equity attributable to HCA Healthcare, Inc.	9,651	9,390
Noncontrolling interests	1,538	1,513
Total stockholders' deficit	11,189	10,903
Total liabilities and stockholders' deficit	18,266	18,167
Eliminations [Member]
Current assets:
Investments in and advances to affiliates	(27,671)	(27,045)
Total assets	(27,671)	(27,045)
Current liabilities:
Stockholders' (deficit) equity attributable to HCA Healthcare, Inc.	(27,671)	(27,045)
Total stockholders' deficit	(27,671)	(27,045)
Total liabilities and stockholders' deficit	$ (27,671)	$ (27,045)

Supplemental Condensed Consol54

Supplemental Condensed Consolidating Financial Information and Other Collateral-Related Information - Schedule of Condensed Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net income (loss)	$ 777	$ 811
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Changes in operating assets and liabilities	(1,180)	(1,146)
Provision for doubtful accounts	760	790
Depreciation and amortization	521	479
Income taxes	292	360
Gains on sales of facilities	(1)	1
Legal claim costs		12
Amortization of debt issuance costs	8	10
Share-based compensation	73	65
Equity in earnings of affiliates	0	0
Other	30	17
Net cash provided by (used in) operating activities	1,280	1,399
Cash flows from investing activities:
Purchase of property and equipment	(571)	(509)
Acquisition of hospitals and health care entities	(90)	(9)
Disposition of hospitals and health care entities	4	4
Change in investments	(19)	11
Other	7	7
Net cash used in investing activities	(669)	(496)
Cash flows from financing activities:
Issuance of long-term debt		3,000
Net change in revolving credit facilities	160	(930)
Repayment of long-term debt	(43)	(2,011)
Distributions to noncontrolling interests	(145)	(111)
Payment of debt issuance costs	(2)	(22)
Repurchases of common stock	(424)	(621)
Other	(50)	(97)
Net cash (used in) provided by financing activities	(504)	(792)
Change in cash and cash equivalents	107	111
Cash and cash equivalents at beginning of period	646	741
Cash and cash equivalents at end of period	753	852
Eliminations [Member]
Cash flows from operating activities:
Net income (loss)	(608)	(629)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Equity in earnings of affiliates	608	629
HCA Healthcare, Inc. Issuer [Member]
Cash flows from operating activities:
Net income (loss)	659	694
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Changes in operating assets and liabilities	(15)	(36)
Income taxes	292	360
Equity in earnings of affiliates	(608)	(629)
Other	19	19
Net cash provided by (used in) operating activities	347	408
Cash flows from financing activities:
Repurchases of common stock	(424)	(621)
Changes in intercompany balances with affiliates, net	134	311
Other	(57)	(97)
Net cash (used in) provided by financing activities	(347)	(407)
Change in cash and cash equivalents		1
Cash and cash equivalents at beginning of period		0
Cash and cash equivalents at end of period		1
HCA Inc. Issuer [Member]
Cash flows from operating activities:
Net income (loss)	(463)	(418)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Changes in operating assets and liabilities	(295)	(67)
Legal claim costs		12
Amortization of debt issuance costs	8	10
Net cash provided by (used in) operating activities	(750)	(463)
Cash flows from financing activities:
Issuance of long-term debt		3,000
Net change in revolving credit facilities	160	(930)
Repayment of long-term debt	(18)	(1,980)
Payment of debt issuance costs	(2)	(22)
Changes in intercompany balances with affiliates, net	610	395
Net cash (used in) provided by financing activities	750	463
Subsidiary Guarantors [Member]
Cash flows from operating activities:
Net income (loss)	841	772
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Changes in operating assets and liabilities	(601)	(740)
Provision for doubtful accounts	419	494
Depreciation and amortization	251	227
Gains on sales of facilities		2
Share-based compensation	73	65
Other		(4)
Net cash provided by (used in) operating activities	983	816
Cash flows from investing activities:
Purchase of property and equipment	(229)	(161)
Acquisition of hospitals and health care entities	(5)
Disposition of hospitals and health care entities	4
Net cash used in investing activities	(230)	(161)
Cash flows from financing activities:
Repayment of long-term debt	(16)	(17)
Distributions to noncontrolling interests	(57)	(16)
Changes in intercompany balances with affiliates, net	(608)	(556)
Net cash (used in) provided by financing activities	(681)	(589)
Change in cash and cash equivalents	72	66
Cash and cash equivalents at beginning of period	110	155
Cash and cash equivalents at end of period	182	221
Subsidiary Non-Guarantors [Member]
Cash flows from operating activities:
Net income (loss)	348	392
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Changes in operating assets and liabilities	(269)	(303)
Provision for doubtful accounts	341	296
Depreciation and amortization	270	252
Gains on sales of facilities	(1)	(1)
Other	11	2
Net cash provided by (used in) operating activities	700	638
Cash flows from investing activities:
Purchase of property and equipment	(342)	(348)
Acquisition of hospitals and health care entities	(85)	(9)
Disposition of hospitals and health care entities		4
Change in investments	(19)	11
Other	7	7
Net cash used in investing activities	(439)	(335)
Cash flows from financing activities:
Repayment of long-term debt	(9)	(14)
Distributions to noncontrolling interests	(88)	(95)
Changes in intercompany balances with affiliates, net	(136)	(150)
Net cash (used in) provided by financing activities	(226)	(259)
Change in cash and cash equivalents	35	44
Cash and cash equivalents at beginning of period	536	586
Cash and cash equivalents at end of period	$ 571	$ 630